GenLumina
↗Leiden, Netherlands
GenLumina is a Leiden, Netherlands-based biotechnology startup founded in 2024. The company specializes in developing light-activated DNA nanomedicines, specifically utilizing ultra-small DNA-encapsulated silver nanoclusters that target tumor cell nuclei. When activated by light, these nanoclusters induce controlled cancer cell death while sparing healthy tissue.
The company's platform aims to provide a minimally invasive, highly targeted therapeutic approach for oncology. GenLumina is currently in the preclinical stage, focusing on colorectal cancer as its first target indication, and is actively seeking partnerships and further funding to advance toward clinical trials.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$1.5M+
Investors:UNIIQ
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:DNA nanotechnology, Nanomedicine
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Leiden University Medical Center (LUMC), Dutch Cancer Institute
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Donny de Bruin - Founding Partner & Chief Scientific Officer
Dirk Bouwmeester - Founding Partner & Patent Officer
Gerco Kanbier - Founding Partner & Managing Director
Scientific Founders:Donny de Bruin, Dirk Bouwmeester, Gerco Kanbier
LINKS
Website:genlumina.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of GenLumina and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with GenLumina. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.